prednisolone steaglate - PMC

PMC Images search for prednisolone steaglate

Figure 5

Relative expression of C3, HO-1 and HSP-70. Ratio of Bcl2/BAX expression. A) Kidney samples. C3 (Sham operated + Saline: 0.18 ± 0.04; Sham operated + prednisolone treatment: 0.16 ± 0.02; BD + Saline: 17.27 ± 10.74; BD + prednisolone treatment: 1.47 ± 0.26), HO-1 (Sham operated + Saline: 0.03 ± 0.01; Sham operated + prednisolone treatment: 0.04 ± 0.01; BD + Saline: 3.05 ± 2.06; BD + prednisolone treatment: 0.42 ± 0.23), HSP-70 (Sham operated + Saline: 0.06 ± 0.09; Sham operated + prednisolone treatment: 0.03 ± 0.07; BD + Saline: 0.03 ± 0.02; BD + prednisolone treatment: 0.03 ± 0.01), Ratio Bcl2/BAX (Sham operated + Saline: 0.37 ± 0.15; Sham operated + prednisolone treatment: 0.38 ± 0.15; BD + Saline: 0.69 ± 0.19; BD + prednisolone treatment: 0.69 ± 0.28). B) Liver samples. C3 (Sham operated + Saline: 546.9 ± 109.4; Sham operated + prednisolone treatment: 534.2 ± 92.18; BD + Saline: 687.4 ± 96.13; BD + prednisolone treatment: 952.2 ± 125.3), HO-1 (Sham operated + Saline: 0.47 ± 0.11; Sham operated + prednisolone treatment: 0.45 ± 0.13; BD + Saline: 5.78 ± 2.65; BD + prednisolone treatment: 12.47 ± 4.96), HSP-70 (Sham operated + Saline: 0.05 ± 0.09; Sham operated + prednisolone treatment: 0.05 ± 0.11; BD + Saline: 0.03 ± 0.04; BD + prednisolone treatment: 0.003 ± 0.005), Ratio Bcl2/BAX (Sham operated + Saline: 0.18 ± 0.03; Sham operated + prednisolone treatment: 0.18 ± 0.01; BD + Saline: 0.05 ± 0.01; BD + prednisolone treatment: 0.05 ± 0.01).

Prednisolone has a positive effect on the kidney but not on the liver of brain dead rats: a potencial role in complement activation

J Transl Med. 2014;12:111-111.
Figure 4

Relative expression of inflammatory genes.A) Kidney samples. IL-6 (Sham operated + Saline: 0.08 ± 0.09; Sham operated + prednisolone treatment: 0.05 ± 0.05; BD + Saline: 6.04 ± 3.79; BD + prednisolone treatment: 0.34 ± 0.59), IL-1 β (Sham operated + Saline: 0.89 ± 0.22; Sham operated + prednisolone treatment: 0.27 ± 0.11; BD + Saline: 1.95 ± 0.69; BD + prednisolone treatment: 0.40 ± 0.30), TNF- α (Sham operated + Saline: 0.69 ± 0.34; Sham operated + prednisolone treatment: 0.20 ± 0.10; BD + Saline: 0.99 ± 0.49; BD + prednisolone treatment: 0.20 ± 0.16), MCP-1 (Sham operated + Saline: 0.46 ± 0.13; Sham operated + prednisolone treatment: 0.13 ± 0.07; BD + Saline 4.46 ± 1.02; BD + prednisolone treatment: 0.39 ± 0.44). B) Liver samples. IL-6 (Sham operated + Saline: 0.11 ± 0.05; Sham operated + prednisolone treatment: 0.04 ± 0.03; BD + Saline: 2.98 ± 0.84; BD + prednisolone treatment: 0.60 ± 0.45), IL-1 β (Sham operated + Saline: 1.09 ± 0.42; Sham operated + prednisolone treatment: 0.50 ± 0.20; BD + Saline: 1.91 ± 0.27; BD + prednisolone treatment: 0.61 ± 0.26), TNF- α (Sham operated + Saline: 7.91 ± 2.13; Sham operated + prednisolone treatment: 4.51 ± 1.57; BD + Saline: 4.04 ± 0.66; BD + prednisolone treatment: 1.3 ± 0.71), MCP-1 (Sham operated + Saline: 0.71 ± 0.17; Sham operated + prednisolone treatment: 0.32 ± 0.09; BD + Saline: 1.06 ± 0.23; BD + prednisolone treatment: 0.36 ± 0.24).

Prednisolone has a positive effect on the kidney but not on the liver of brain dead rats: a potencial role in complement activation

J Transl Med. 2014;12:111-111.
Figure 2

Plasmatic levels of kidney function markers and liver injury markers. Creatinine (Sham operated + Saline: 36 ± 9.24 μM; Sham operated + prednisolone treatment: 36.88 ± 4.29 μM; BD + Saline 86.63 ± 18.37 μM; BD + prednisolone treatment: 50.38 ± 6.91 μM), AST (Sham operated + Saline: 71.50 ± 14.19 U/l; Sham operated + prednisolone treatment: 72.88 ± 11.66 U/l; BD + Saline: 138.0 ± 72.76 U/l; BD + prednisolone treatment: 146.3 ± 35.07 U/l), ALT (Sham operated + Saline: 54.38 ± 13.97 U/l; Sham operated + prednisolone treatment: 45.88 ± 15.82 U/l; BD + Saline: 106.3 ± 58.38 U/l; BD + prednisolone treatment: 87.50 ± 18.33 U/l), LDH (Sham + Saline: 157.1 ± 41.54 U/l; Sham + prednisolone treatment: 172.4 ± 104.2 U/l; BD + Saline: 342.8 ± 228.0 U/l; BD + prednisolone treatment: 270 ± 152.9 U/l) and IL-6 (Sham operated + Saline: 15.63 ± 29.69 pg/ml; Sham operated + prednisolone: undetectable; BD + Saline: 2.07 × 10 ⁵± 9.59 × 10 ⁴ pg/ml; BD + prednisolone treatment: 1.18 × 10 ³± 2.69 × 10 ³ pg/ml).

Prednisolone has a positive effect on the kidney but not on the liver of brain dead rats: a potencial role in complement activation

J Transl Med. 2014;12:111-111.
Figure 2Silencing of lncRNAs upregulated in cALL increases apoptosis in response to cytotoxic treatment

A. Increased apoptosis with doxorubicin and prednisolone treatment measured by AnnexinV / propidium iodide staining. NALM-6 cells transfected with dsiRNA against RP11-137H2.4 were treated with 150 nM doxorubicin for 24 hours or with 750 µM prednisolone for 20 hours. DMSO was used as vehicle control for prednisolone. B. Increased apoptosis with doxorubicin and prednisolone treatment measured by AnnexinV / propidium iodide staining. NALM-6 cells transfected with dsiRNA against KB-208E9.1 were treated with 150 nM doxorubicin for 24 hours or with 750 µM prednisolone for 20 hours. DMSO was used as vehicle control for prednisolone. C. Increased apoptosis with doxorubicin and prednisolone treatment measured by AnnexinV / propidium iodide staining. NALM-6 cells transfected with dsiRNAs against AC156455.1 were treated with 150 nM doxorubicin for 24 hours or with 750 µM prednisolone for 20 hours. DMSO was used as vehicle control for prednisolone. D. Increased apoptosis with camptothecin treatment measured by AnnexinV / propidium iodide staining. NALM-6 cells transfected with siRNA against CTA-331P3.1 were treated with 500 nM camptothecin for 24 hours. Control cells were transfected with negative control siRNA/dsiRNA (see Methods). Comparisons were made using a two-tailed T-test. *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001.

A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration

Oncotarget. 2017 Jan 31;8(5):7477-7488.